Labcorp® Plasma Focus™

Tumor genomic profiling can be complicated, especially for diseases that commonly have multiple different genomic biomarkers of interest, such as non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).

 

Labcorp Plasma Focus is an actionable liquid biopsy test that can help simplify the process of tumor genomic profiling and targeted therapy selection. The test includes a 33-gene panel that assesses genomic alterations (including SNVs, indels, amplification and translocations), as well as Microsatellite instability (MSI) status. It delivers a clear report that focuses on FDA-approved, guideline-driven biomarkers for patients with advanced solid cancers.

 

In this webinar, Mark Sausen, PhD, head of technology innovation at Labcorp, discusses Labcorp Plasma Focus, including its test components, reporting structure and how the test compares to tissue-based tumor profiling. He also hosts a Q&A session with Dr. Mohamad Khasawneh, a hematologist oncologist at Pikeville Leonard Lawson Cancer Center. Together, they discuss which patients are most likely to benefit from liquid biopsy-based testing, how liquid biopsy can complement (rather than replace) tissue profiling and Dr. Khasawneh’s experience using Labcorp Plasma Focus test in the field.

 

Learning Objectives